Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
Otani, Koichi
Mihara, Kazuo
Okada, Motohiro
Kaneko, Sunao
and
Fukushima, Yutaka
1991.
Crossover reaction between haloperidol and amoxapine for NMS.
British Journal of Psychiatry,
Vol. 159,
Issue. 6,
p.
889.
White, D. A. C.
1992.
Catatonia and the Neuroleptic Malignant Syndrome – a Single Entity?.
British Journal of Psychiatry,
Vol. 161,
Issue. 4,
p.
558.
Hosty, Gary
1992.
Neuroleptic malignant syndrome in two sisters.
Irish Journal of Psychological Medicine,
Vol. 9,
Issue. 2,
p.
122.
Otani, K.
Mihara, K.
Kondo, T.
Okada, M.
Kaneko, S.
and
Fukushima, Y.
1992.
Treatment of neuroleptic malignant syndrome with levodopa.
Human Psychopharmacology: Clinical and Experimental,
Vol. 7,
Issue. 3,
p.
217.
Gurrera, Ronald J.
and
Romero, Jorge A.
1992.
Sympathoadrenomedullary activity in the neuroleptic malignant syndrome.
Biological Psychiatry,
Vol. 32,
Issue. 4,
p.
334.
Capellà, Dolors
and
Figueras, Albert
1992.
Vol. 16,
Issue. ,
p.
39.
Caroff, Stanley N.
and
Mann, Stephan C.
1993.
Neuroleptic malignant syndrome.
Medical Clinics of North America,
Vol. 77,
Issue. 1,
p.
185.
Huckle, Phil
Kellam, Alexander
Williams, Peter
Tanaghow, Amgad
and
Lloyd, Alan
1993.
Do cases of neuroleptic malignant syndrome cluster?.
Irish Journal of Psychological Medicine,
Vol. 10,
Issue. 1,
p.
28.
Tanaka, Osamu
Otani, Koichi
Kondo, Tsuyoshi
Kaneko, Sunao
and
Fukushima, Yutaka
1993.
Paralytic ileus as a prodromal symptom of the neuroleptic malignant syndrome.
Human Psychopharmacology: Clinical and Experimental,
Vol. 8,
Issue. 5,
p.
367.
Qureshi, Naseem Akhtar
1993.
Neuroleptic Malignant Syndrome: Risk Factors!.
Annals of Saudi Medicine,
Vol. 13,
Issue. 1,
p.
106.
Okada, Fumihiko
Sasa, Hiroshi
Otani, Koichi
Kaneko, Sunao
Fukushima, Yutaka
and
Nomura, Kazuo
1993.
Letters.
Human Psychopharmacology: Clinical and Experimental,
Vol. 8,
Issue. 5,
p.
371.
Caroff, Stanley N.
Mann, Stephan C.
and
Campbell, E. Cabrina
1994.
HYPERTHERMIA AND NEUROLEPTIC MALIGNANT SYNDROME.
Anesthesiology Clinics of North America,
Vol. 12,
Issue. 3,
p.
491.
Tu, Jun‐Bi
1994.
Theory and practice of psychopharmacogenetics.
American Journal of Medical Genetics,
Vol. 54,
Issue. 4,
p.
391.
Ram, Anca
Cao, Qiuhe
Keck, Paul E.
Pope, Harrison G.
Otani, Koichi
Addonizio, Gerard
McElroy, Susan L.
Kaneko, Sunao
Redlichova, Michaela
Gershon, Elliot S.
and
Gejman, Pablo V.
1995.
Structural change in dopamine D2 receptor gene in a patient with neuroleptic malignant syndrome.
American Journal of Medical Genetics,
Vol. 60,
Issue. 3,
p.
228.
Nogué, S.
Nolla, J.
Marruecos, L.
and
Muriné, P.
1996.
Human Toxicology.
p.
281.
Ishida, M.
Otani, K.
Kaneko, S.
Ishida, H.
and
Kawashima, S.
1996.
Hyperglycemia as a symptom of neuroleptic malignant syndrome.
Human Psychopharmacology: Clinical and Experimental,
Vol. 11,
Issue. 2,
p.
137.
Ueno, Shu-ichi
Otani, Koichi
Kaneko, Sunao
Koshiro, Kazuko
Kondoh, Keiji
Kotani, Yasunori
and
Sano, Akira
1996.
Cytochrome P-450 2D6 gene polymorphism is not associated with neuroleptic malignant syndrome.
Biological Psychiatry,
Vol. 40,
Issue. 1,
p.
72.
Manor, Iris
Hermesh, Haggai
Munitz, Hanan
and
Weizman, Abraham
1997.
Neuroleptic malignant syndrome with gangliosidosis type II.
Biological Psychiatry,
Vol. 41,
Issue. 12,
p.
1222.
Kawanishi, Chiaki
Shimoda, Yoshikazu
Fujimaki, Jun
Onishi, Hideki
Suzuki, Kyoko
Hanihara, Tokiji
Sugiyama, Naoya
and
Kosaka, Kenji
1998.
Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome.
Journal of the Neurological Sciences,
Vol. 160,
Issue. 1,
p.
102.
Gurrera, Ronald J.
1999.
Sympathoadrenal Hyperactivity and the Etiology of Neuroleptic Malignant Syndrome.
American Journal of Psychiatry,
Vol. 156,
Issue. 2,
p.
169.
eLetters
No eLetters have been published for this article.